Edition:
India

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

33.35USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$33.35
Open
$33.00
Day's High
$34.20
Day's Low
$32.75
Volume
72,117
Avg. Vol
108,346
52-wk High
$37.45
52-wk Low
$18.42

Select another date:

Thu, Mar 1 2018

Mylan teams up with Revance on biosimilar for Botox

NEW YORK Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

CORRECTED-Mylan teams up with Revance on biosimilar for Botox

NEW YORK, Feb 28 Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14

* REVANCE THERAPEUTICS INC - ‍REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018​

BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍

* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

Select another date: